Rituximab in Refractory Myasthenia Gravis
Myasthenia gravis (MG) from Greek: myos = muscle, asthenos = weakness, and Latin: gravis = severe, is an autoimmune neuromuscular disease primarily mediated by antibodies (Abs) targeting either the nicotinic acetylcholine receptor (AChR), or the components of the postsynaptic membrane at the neuromuscular junction (NMJ) leading to impaired neuromuscular transmission. (1) Standard treatment such as Cholinesterase inhibitors cannot completely relieve the symptoms of MG or prevent the progression of the disease, glucocorticoids are also widely used to treat MG often causing severe adverse effects, and immunosuppressant such as glucocorticosteroids , often used as first-line MG therapies but for long-term use of immunosuppressive agents, often leads to significant side effects
Other
Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing antibodies against acetylcholine receptors (AChR). Cholinesterase inhibitors, Glucocorticoid , which is currently recommended as a first-line treatment for MG, although it has drawbacks, including possible toxicity and inefficiency in patients with refractory MG and traditional immunosuppressants stay the standard treatments at present, but they have demonstrated limitations and often unsatisfactory efficacy so the target specific therapeutic interventions should therefore be directed against antibodies For example, Rituximab is a monoclonal antibody (mAbs) that could be more active and longer lasting with less serious side effects.
